Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy

Published:2013-02 Issue:2 Volume:8 Page:222-228
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

William William N.,Pataer Apar,Kalhor Neda,Correa Arlene M.,Rice David C.,Wistuba Ignacio I.,Heymach John,Lee J. Jack,Kim Edward S.,Munden Reginald,Gold Kathryn A.,Papadimitrakopoulou Vassiliki,Swisher Stephen G.,Erasmus Jeremy J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer;Roth;Lung Cancer,1998

2. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial;Rosell;Lung Cancer,1999

3. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer;Depierre;J Clin Oncol,2002

4. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial;Pisters;J Clin Oncol,2010

5. University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy;Pataer;J Thorac Oncol,2012

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar);European Journal of Radiology;2024-08

2. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis;Cancers;2024-07-08

3. Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review;Journal of Thoracic Disease;2024-07

4. Immune checkpoint inhibition in early-stage non-small cell lung cancer;Lung Cancer;2024-07

5. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review;Journal of Oncology Pharmacy Practice;2024-06-11